TCIM
HEPA

TIAA CREF Investment Management’s Hepion Pharmaceuticals HEPA Stock Holding History

TIAA CREF Investment Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$4.41M – 3081
2016
Q4 		$4.41M Sell
1
-1
-50% -$1.01M ﹤0.01% 1680
2016
Q3 		$5.72K Hold
2
– – ﹤0.01% 1518
2016
Q2 		$3.98M Buy
2
+1
+100% +$559K ﹤0.01% 1710
2016
Q1 		$866K Buy
+1
New +$617K ﹤0.01% 2551
2015
Q4 		– Sell
-1
Closed -$2.08M – 3144
2015
Q3 		$2.08M Buy
+1
New +$2.36M ﹤0.01% 2112

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TIAA CREF Investment Management's HEPA Position: Q1 2017 in Review

TIAA CREF Investment Management sold out of Hepion Pharmaceuticals (HEPA) in Q1 2017, closing a stake of 1 share — an estimated $4.41M sold.

TIAA CREF Investment Management first reported a position in HEPA in Q3 2015 and held it in 5 quarters. The position peaked at $4.41M in Q4 2016. 3 funds tracked by Wall St. Rank hold HEPA as of Q1 2017.

  • TIAA CREF Investment Management reported no remaining Hepion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 1 Hepion Pharmaceuticals share in Q1 2017, an estimated $4.41M.
  • TIAA CREF Investment Management first reported a position in Hepion Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • TIAA CREF Investment Management's Hepion Pharmaceuticals position peaked at $4.41M in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2017.

Based on TIAA CREF Investment Management's 13F filing for Q1 2017, filed 11 May 2017.